Parexel International Corp (PRXL)

62.71
0.36 0.58
NASDAQ : Health Care
Prev Close 62.35
Open 62.59
Day Low/High 62.33 / 63.02
52 Wk Low/High 56.00 / 76.17
Volume 252.66K
Avg Volume 998.50K
Exchange NASDAQ
Shares Outstanding 50.95M
Market Cap 3.23B
EPS 2.90
P/E Ratio 22.57
Div & Yield N.A. (N.A)

Latest News

PAREXEL Ranked A Top CRO In CenterWatch Global Investigative Site Relationship Survey

PAREXEL Ranked A Top CRO In CenterWatch Global Investigative Site Relationship Survey

PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services organization, today announced that it was named a top contract research organization (CRO) in the CenterWatch 2017 Global...

PAREXEL Launches Patient Sensor Solution To Transform Clinical Trial Data Collection

PAREXEL Launches Patient Sensor Solution To Transform Clinical Trial Data Collection

PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced the launch of its patient sensor solution, a new offering that securely captures, transmits, stores,...

PAREXEL Named A FlexJobs Top 100 Company To Watch For Telecommuting And Remote Jobs In 2017

PAREXEL Named A FlexJobs Top 100 Company To Watch For Telecommuting And Remote Jobs In 2017

PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services organization, today announced that it has been named to the FlexJobs Top 100 Companies to Watch for Telecommuting and Remote Jobs...

PAREXEL International Appoints Simon Harford As Senior Vice President And Chief Financial Officer

PAREXEL International Appoints Simon Harford As Senior Vice President And Chief Financial Officer

PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced the appointment of Simon Harford as Senior Vice President and Chief Financial Officer effective June 1,...

PAREXEL International To Participate At Cowen & Co. Health Care Conference And Barclays Global Healthcare Conference

PAREXEL International To Participate At Cowen & Co. Health Care Conference And Barclays Global Healthcare Conference

PAREXEL International Corporation (NASDAQ: PRXL) announced today that executives will be participating at two investor conferences in March.

PAREXEL Launches ClinPhone RTSM Mobile App To Improve Supply Management And Increase Patient Safety

PAREXEL Launches ClinPhone RTSM Mobile App To Improve Supply Management And Increase Patient Safety

PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today launched a mobile app for the ClinPhone ® RTSM (randomization and trial supply management) service.

Short Interest Declines 21.7% For PRXL

Short Interest Declines 21.7% For PRXL

The most recent short interest data has been released for the 01/31/2017 settlement date, which shows a 1,064,898 share decrease in total short interest for PAREXEL International Corp. , to 3,834,977, a decrease of 21.73% since 01/13/2017.

PAREXEL International To Present At Leerink Partners Healthcare Conference

PAREXEL International To Present At Leerink Partners Healthcare Conference

PAREXEL International Corporation (NASDAQ: PRXL) announced today that it will be presenting at the Leerink Partners Healthcare Conference on Thursday, February 16, 2017, in New York City.

Analysts' Actions -- Cabot, International Paper, Range Resources and More

Analysts' Actions -- Cabot, International Paper, Range Resources and More

Here are Monday's top research calls, including upgrades for Cabot Oil & Gas and Range Resources, and a downgrade for International Paper.

Analysts' Actions -- Eaton, Ford, Altria, Ralph Lauren and More

Analysts' Actions -- Eaton, Ford, Altria, Ralph Lauren and More

Here are Friday's top research calls, including an upgrade for Ford and downgrades for Eaton, Altria and Ralph Lauren.

PAREXEL International Reports Second Quarter Fiscal Year 2017 Results

PAREXEL International Reports Second Quarter Fiscal Year 2017 Results

PAREXEL International Corporation (NASDAQ: PRXL) today reported financial results for the second quarter of Fiscal Year 2017, which ended on December 31, 2016.

PAREXEL Announces Definitive Agreement To Acquire The Medical Affairs Company

PAREXEL Announces Definitive Agreement To Acquire The Medical Affairs Company

PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that the Company has entered into a definitive agreement to acquire The Medical Affairs Company, LLC...

PAREXEL's Albert Siu And Anke Nissen Accept A 2017 Training Magazine Training Top 125 Award On Behalf Of The Company. PAREXEL Ranked 38 Among The Top 125 Companies. (Photo: Business Wire)

PAREXEL's Albert Siu And Anke Nissen Accept A 2017 Training Magazine Training Top 125 Award On Behalf Of The Company. PAREXEL Ranked 38 Among The Top 125 Companies. (Photo: Business Wire)

PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that the Company has been recognized among top U.

PAREXEL Expands Managed Access Programs Service Offering

PAREXEL Expands Managed Access Programs Service Offering

PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today launched an expanded Managed Access Programs service.

PAREXEL International Announces Date Of Second Quarter Fiscal Year 2017 Earnings Release And Conference Call

PAREXEL International Announces Date Of Second Quarter Fiscal Year 2017 Earnings Release And Conference Call

PAREXEL International Corporation (NASDAQ: PRXL) will release financial results for the Second Quarter Fiscal Year 2017 on Wednesday, February 1, 2017 after the close of the stock market.

PAREXEL International To Present At JP Morgan Healthcare Conference

PAREXEL International To Present At JP Morgan Healthcare Conference

PAREXEL International Corporation (NASDAQ: PRXL) announced today that it will be presenting at the JP Morgan Healthcare Conference on Tuesday, January 10, 2017, in San Francisco.

PAREXEL International Announces $200 Million Accelerated Share Repurchase Program

PAREXEL International Announces $200 Million Accelerated Share Repurchase Program

PAREXEL International Corporation (Nasdaq:PRXL), a leading global biopharmaceutical services provider, announced today that the Company entered into an accelerated share repurchase agreement (ASR) with HSBC Bank USA,...

PAREXEL International To Participate In Evercore ISI MedTools Conference

PAREXEL International To Participate In Evercore ISI MedTools Conference

PAREXEL International Corporation (NASDAQ: PRXL) announced today that it will be attending the Evercore ISI MedTools Conference in Boston.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Concerning Possible Violations Of Federal Securities Laws By Certain Officers And Directors Of PAREXEL International Corporation

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Concerning Possible Violations Of Federal Securities Laws By Certain Officers And Directors Of PAREXEL International Corporation

Levi & Korsinsky announces it has commenced an investigation of PAREXEL International Corporation (NASDAQ: PRXL) ("PAREXEL") concerning possible violations of federal securities laws by the Company and/or certain of its...

PAREXEL Launches IDMP-Focused Software And Service Solution

PAREXEL Launches IDMP-Focused Software And Service Solution

PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today launched an Identification of Medicinal Products (IDMP)-focused solution for biopharmaceutical companies.

EQUITY ALERT: Goldberg Law PC Announces An Investigation Of Claims Against PAREXEL International Corporation And Advises Investors With Losses To Contact The Firm

EQUITY ALERT: Goldberg Law PC Announces An Investigation Of Claims Against PAREXEL International Corporation And Advises Investors With Losses To Contact The Firm

Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating PAREXEL International Corporation ("PAREXEL" or the "Company") (Nasdaq: PRXL) concerning possible violations of federal...

INVESTOR LOSS ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against PAREXEL International Corporation - PRXL

INVESTOR LOSS ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against PAREXEL International Corporation - PRXL

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of PAREXEL International Corporation (NASDAQ:PRXL) resulting from allegations that...